Kevin is Senior Director of Preclinical Development at Therna Biosciences, where he leads translational preclinical strategy to advance AI-optimized mRNA therapeutics toward the clinic.

He brings over 25 years of experience in molecular biology research, including extensive industry experience spanning discovery, design, screening, in vitro validation, and preclinical pharmacology. His work bridges internal teams with external partners, including KOLs and CROs, to define critical-path experiments that enable informed go/no-go decisions across diverse therapeutic modalities and disease areas.

Kevin earned his Ph.D. in Molecular, Cellular, and Developmental Biology from the University of California, Santa Barbara, where his research focused on targeted therapeutic approaches for autosomal dominant polycystic kidney disease.